A potential benzimidazole-derived compound, NSC348884, combats carbapenem-resistant gram-negative bacteria - PubMed
4 hours ago
- #Antimicrobial Resistance
- #CRAB
- #Drug Development
- NSC348884, a benzimidazole-derived compound, shows promise against carbapenem-resistant gram-negative bacteria (CR-GNB).
- It exhibits direct antibacterial efficacy without inducing resistance and has anti-biofilm activity comparable to polymyxin B (PMB).
- Mechanistically, NSC348884 disrupts lipid metabolic homeostasis and membrane integrity, leading to ROS burst, growth inhibition, and bacterial death.
- In a mouse model of CRAB infection, NSC348884 reduced bacterial load and protected against lung injury and inflammation.
- NSC348884 is a promising drug candidate for treating CRAB infections.